Omalizumab

Omalizumab
Omalizumab structure: (A) murine complementarity-determining region and (B) IgG1κ human framework
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetIgE Fc region
Clinical data
Pronunciation/ˌoʊməˈlɪzumæb/
OH-mə-LI-zoo-mab
Trade namesXolair
BiosimilarsOmalizumab-igec, Omlyclo
AHFS/Drugs.comMonograph
MedlinePlusa603031
License data
Pregnancy
category
  • AU: B1
Routes of
administration
Subcutaneous
ATC code
Legal status
Legal status
Pharmacokinetic data
Elimination half-life26 days
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC6450H9916N1714O2023S38
Molar mass145058.53 g·mol−1

Omalizumab, sold under the brand name Xolair among others, is an injectable medication to treat severe persistent allergic forms of asthma, nasal polyps, urticaria (hives), and immunoglobulin E-mediated food allergy.

Omalizumab is a recombinant DNA-derived humanized IgG1 monoclonal antibody which specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to the membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes.

In 1987, Tanox filed its first patent application on the anti-IgE drug candidate. Omalizumab was approved for medical use in the United States in June 2003, and authorized in the European Union in October 2005.